Thymosin Alpha 1 RDGR - 10MG

Thymosin Alpha 1 RDGR

Thymosin Alpha 1 (Tα1) is a 28–amino acid peptide central to T-cell maturation and immune regulation. Synthetic Tα1 (thymalfasin) is approved in several countries for chronic hepatitis B/C, used as an immune enhancer in immunocompromised populations, and as an adjunct in cancer and severe infections; it has also seen use in China for cancer and emergency deployment during SARS/COVID-19.^[1–6]

Mechanism of Action & Immunomodulation

• Activates innate and adaptive immunity (T, B, NK cells; macrophages; dendritic cells) via TLR2/3/4/7/9 and downstream NF-κB, IRF3, MyD88, p38 MAPK signaling, restoring immune competence in suppressed states.^{[2–4,7–10]}
• Modulates dendritic cell function, supports immune tolerance (IDO activation), and blocks steroid-induced thymocyte apoptosis.^[8,9]

Clinical Applications

• Viral infections: Enhances responses in HBV/HCV/HIV; in severe COVID-19, reduced mortality with restoration of lymphocyte counts and reversal of T-cell exhaustion.^[2,4–6]
• Cancer: Adjuvant in solid tumors (e.g., NSCLC, HCC); improves survival, reduces chemo-induced lymphopenia, and may synergize with chemotherapy/ICIs by “heating up” cold tumors and lowering irAEs.^[1,3,11]
• Sepsis: Meta-analyses show reduced mortality and improved inflammatory/immune markers (better APACHE II scores).^[1,12]
• Immunodeficiency & vaccines: Enhances vaccine responses and immune restoration in aging, chemotherapy, and critical illness.^[1,4,7–10]

Safety & Tolerability

• Extensive clinical exposure (>11,000 subjects) shows Tα1 is well tolerated with AEs comparable to placebo; most commonly mild local injection reactions.^[4,5,13]
• No signal for pathologic autoimmunity or tumorigenesis in long-term use.^{[1,4,7–9,13]}

Summary

Thymosin Alpha 1 RDGR is a pleiotropic immunomodulator with robust evidence across viral infections, oncology adjuvancy, and sepsis, coupling multi-pathway immune restoration with a strong safety profile.^[1–13]

References

1. Mao L. Int Immunopharmacol. 2023;117:109952.
2. Tao N, Xu X, Ying Y, et al. Molecules. 2023;28(8):3539.
3. Wei Y, Zhang Y, Li P, et al. Int Immunopharmacol. 2023;117:109744.
4. Camerini R, Garaci E. Expert Opin Biol Ther. 2015;15(S1):S117-27.
5. Ancell CD, Phipps J, Young L. Am J Health-Syst Pharm. 2001;58(10):879-85.
6. Liu Y, Pan Y, Hu Z, et al. Clin Infect Dis. 2020;71(16):2150-57.
7. King R, Tuthill C. Vitam Horm. 2016;102:151-78.
8. Romani L, Moretti S, Fallarino F, et al. Ann N Y Acad Sci. 2012;1269:1-6.
9. Romani L, Bistoni F, Montagnoli C, et al. Ann N Y Acad Sci. 2007;1112:326-38.
10. Naylor PH, Quadrini K, Garaci E, et al. Ann N Y Acad Sci. 2007;1112:235-44.
11. Garaci E, Pica F, Serafino A, et al. Ann N Y Acad Sci. 2012;1269:26-33.
12. Liu F, Wang HM, Wang T, et al. BMC Infect Dis. 2016;16:488.
13. Dinetz E, Lee E. Alt Ther Health Med. 2024;30(1):6-12.

All information provided is for research purposes only.

All COA’s avail upon request by email info@truformlabs.com.

All information provided is for research purposes only.

Storage & Handling (Research Use)

• Lyophilized (dry) vials: Store sealed at −20 °C to −80 °C (long-term), desiccated and protected from light. Short-term (≤2–3 weeks) at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot immediately and freeze at −20 °C to −80 °C for up to 3 months.
• Avoid degradation: Prepare small aliquots to avoid repeat freeze–thaw; keep solutions on ice during handling; minimize air/light exposure.
• Solvent & pH: Reconstitute per protocol (e.g., sterile saline or bacteriostatic water) at ~pH 7.0–7.4; avoid reactive metals/oxidizers.
• Labeling: Note concentration, solvent, and prep date on all aliquots; follow lab SOPs and any lot-specific stability guidance.

All information provided is for research purposes only.